Filing Flows › Nurix Therapeutics (NRIX) › Q2 FY25
Nurix Therapeutics (NRIX) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed Jul 9, 2025
Nurix Therapeutics (NRIX) reported revenue of $44.1M for the second quarter fiscal 2025 (Q2 FY25), +264% from a year earlier and +139% from the quarter before. Operating margin was -109.7%, net loss $43.5M (98.7% of revenue).
Nurix Therapeutics, Q2 FY25: revenue $44.1M (+264% year over year), operating margin -109.7%, net loss $43.5M, operating cash flow −$63.2M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.1M | +139% | +264% |
| Operating profit | −$48.3M | — | — |
| Net earnings | −$43.5M | — | — |
| Operating cash flow | −$63.2M | — | — |
What changed
Revenue was $44.1M in Q2 FY25, up 264% year over year and up 139% from the previous quarter. License revenue was the largest line at 68% of revenue. Collaboration revenue added $2.0M year over year (up 16%), 6% of the total change.
Operating costs exceeded revenue by $48.3M, an operating margin of -109.7%. Total costs grew 52% against revenue growth of 264%. The fastest-growing cost line was Research & development (+60%). The quarter ended with a net loss of $43.5M, narrower than the previous quarter's $56.4M loss.
Operating cash flow was −$63.2M. Non-cash charges added back $2.2M of depreciation and amortization and $10.4M of share-based compensation. Working capital and other items used $32.3M. Capital expenditures of $2.7M exceeded it, leaving free cash flow of −$65.8M.
Questions
What was Nurix Therapeutics' revenue in the second quarter fiscal 2025?
Nurix Therapeutics (NRIX) reported revenue of $44.1M for the second quarter fiscal 2025 (Q2 FY25), +264% from a year earlier and +139% from the quarter before.
Was Nurix Therapeutics profitable in the second quarter fiscal 2025?
Operating loss was $48.3M (-109.7% of revenue) and net loss $43.5M.
Source: Nurix Therapeutics 10-Q on SEC EDGAR.